Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Context Therapeutics Inc.

Contributing Author

Recent Articles by Context Therapeutics Inc.

Sep-09
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 CNTX GlobeNewswire
Aug-05
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress CNTX +11.45% CNTX -27.27% GlobeNewswire
Jul-10
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CNTX +9.82% GlobeNewswire
Jul-06
Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes CNTX CNTX +9.79% GlobeNewswire
Jun-15
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 CNTX -51.14% GlobeNewswire
Jun-09
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CNTX -11.11% GlobeNewswire
May-27
Context Therapeutics to Present at the Jefferies Global Healthcare Conference CNTX +13.31% GlobeNewswire
May-18
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 CNTX GlobeNewswire
May-06
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results CNTX GlobeNewswire
Apr-02
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer CNTX GlobeNewswire
Mar-23
Context Therapeutics Reports Full Year 2025 Operating and Financial Results CNTX CNTX +5.30% GlobeNewswire
Mar-19
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 CNTX GlobeNewswire
Feb-09
Context Therapeutics to Participate in Upcoming Investor Conferences CNTX GlobeNewswire
Jan-16
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNTX -5.26% CNTX +6.94% GlobeNewswire
Nov-07
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting CNTX GlobeNewswire
Nov-05
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results CNTX CNTX -5.31% GlobeNewswire
Oct-28
Context Therapeutics to Participate in Upcoming Investor Conferences CNTX GlobeNewswire
Oct-06
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting CNTX +10.00% GlobeNewswire
Oct-03
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CNTX +10.03% GlobeNewswire
Aug-27
Context Therapeutics to Participate in Upcoming Investor Conferences CNTX GlobeNewswire
Aug-06
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results CNTX GlobeNewswire
Jun-02
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting CNTX GlobeNewswire
May-29
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer CNTX GlobeNewswire
May-12
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNTX CNTX +5.14% GlobeNewswire
May-07
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results CNTX GlobeNewswire
May-05
Context Therapeutics Announces Chief Medical Officer Transition CNTX GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)